KR100246154B1 - 수용성 캠프토테신 유도체 - Google Patents

수용성 캠프토테신 유도체 Download PDF

Info

Publication number
KR100246154B1
KR100246154B1 KR1019920019884A KR920019884A KR100246154B1 KR 100246154 B1 KR100246154 B1 KR 100246154B1 KR 1019920019884 A KR1019920019884 A KR 1019920019884A KR 920019884 A KR920019884 A KR 920019884A KR 100246154 B1 KR100246154 B1 KR 100246154B1
Authority
KR
South Korea
Prior art keywords
lower alkyl
camptothecin
compound
ethylenedioxy
methylenedioxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019920019884A
Other languages
English (en)
Korean (ko)
Inventor
조셉 루지오 마이클
엠. 베스터맨 제프리
쥐. 에반스 마이클
레슬리 마이어스 피터
Original Assignee
글락소 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소 인크 filed Critical 글락소 인크
Application granted granted Critical
Publication of KR100246154B1 publication Critical patent/KR100246154B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
KR1019920019884A 1991-10-29 1992-10-28 수용성 캠프토테신 유도체 Expired - Fee Related KR100246154B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78427591A 1991-10-29 1991-10-29
US91/784,275 1991-10-29
US82672992A 1992-01-28 1992-01-28
US92/826,729 1992-01-28

Publications (1)

Publication Number Publication Date
KR100246154B1 true KR100246154B1 (ko) 2000-04-01

Family

ID=27120258

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920019884A Expired - Fee Related KR100246154B1 (ko) 1991-10-29 1992-10-28 수용성 캠프토테신 유도체

Country Status (25)

Country Link
EP (1) EP0540099B1 (OSRAM)
JP (2) JP3020760B2 (OSRAM)
KR (1) KR100246154B1 (OSRAM)
CN (1) CN1072683A (OSRAM)
AP (1) AP306A (OSRAM)
AT (1) ATE136898T1 (OSRAM)
AU (1) AU657007B2 (OSRAM)
CA (1) CA2081580A1 (OSRAM)
CZ (1) CZ284023B6 (OSRAM)
DE (1) DE69209969T2 (OSRAM)
DK (1) DK0540099T3 (OSRAM)
ES (1) ES2086643T3 (OSRAM)
FI (3) FI982185A7 (OSRAM)
GR (1) GR3020120T3 (OSRAM)
HU (2) HU217970B (OSRAM)
IL (1) IL103571A (OSRAM)
IS (1) IS1708B (OSRAM)
MX (1) MX9206211A (OSRAM)
MY (1) MY108261A (OSRAM)
NO (1) NO302073B1 (OSRAM)
NZ (1) NZ244914A (OSRAM)
OA (1) OA09767A (OSRAM)
RU (1) RU2119921C1 (OSRAM)
SK (1) SK279298B6 (OSRAM)
TW (1) TW221994B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012096832A3 (en) * 2011-01-12 2013-01-10 Crystal Biopharmaceutical Llc Hdac inhibiting derivatives of camptothecin

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364858A (en) * 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
US6005537A (en) 1992-08-21 1999-12-21 Hitachi, Ltd. Liquid-crystal display control apparatus
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
EP1250926B1 (en) * 1993-01-15 2008-03-12 The Stehlin Foundation For Cancer Research Use of a water-insoluble S-camptothecin with a closed lactone ring in the manufacture of a medicament for treatment of colon cancer
US5369127A (en) * 1993-04-21 1994-11-29 Allergan, Inc. 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents
IS4152A (is) * 1993-04-29 1994-10-30 Glaxo Inc. Vatnsuppleysanlegar Camptothecin afleiður og aðferð til framleiðslu þeirra
EP0699201A1 (en) * 1993-05-03 1996-03-06 Smithkline Beecham Corporation SUBSTITUTED METHYLENEDIOXY 3',4':6,7]INDOLIZINO- 1,2-$i(b)]QUINOLINONES
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
IT1269862B (it) * 1994-05-30 1997-04-15 Indena Spa Alcaloidi da mappia foetida, loro uso e formulazioni che li contengono
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
KR960029336A (ko) 1995-01-09 1996-08-17 김충환 캄토테신 유도체, 그의 제조 방법 및 이를 함유하는 항암제
US5496952A (en) * 1995-02-07 1996-03-05 North Carolina State University Method of making asymmetric DE ring intermediates for the synthesis of camptothecin and camptothecin analogs
US5670500A (en) * 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
EP0837850B1 (en) * 1995-06-27 2004-09-01 Takeda Chemical Industries, Ltd. 4-acylamino(halogeno) alkyl-quinoline derivatives, their preparation and their use as melatonin agonists
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
AU7732996A (en) * 1995-11-22 1997-06-11 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
RU2214412C2 (ru) * 1996-06-27 2003-10-20 Лиганд Фармасетикалз Инкорпорейтед ПРОИЗВОДНЫЕ 8-ПИРИДОНО [5,6g] ХИНОЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБЫ С ИХ ИСПОЛЬЗОВАНИЕМ
SG116433A1 (en) 1996-10-30 2005-11-28 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof.
US6559309B2 (en) 1996-11-01 2003-05-06 Osi Pharmaceuticals, Inc. Preparation of a camptothecin derivative by intramolecular cyclisation
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
US6046209A (en) * 1997-05-27 2000-04-04 Smithkline Beecham Corporation Water soluble camptothecin analogs
PT1233787E (pt) * 1999-11-09 2005-04-29 Conseils Rech S Et D Applic Sc Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
HRP20020658A2 (en) 2000-02-28 2004-12-31 Aventis Pharma Sa A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
HRP20030382A2 (en) 2000-10-27 2005-04-30 Aventis Pharma S.A. A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
US20090104254A1 (en) 2004-12-22 2009-04-23 Rutgers, The State University Of New Jersey Controlled Release Hydrogels
CA2658015A1 (en) 2006-03-30 2007-10-11 Diatos S.A. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
CN101407524B (zh) * 2007-10-09 2012-07-18 江苏先声药物研究有限公司 噁嗪骈喜树碱衍生物及其制备方法和用途
CN100592871C (zh) * 2008-03-14 2010-03-03 浙江林学院 一种杀虫剂组合物及其加工方法
ES2373172B1 (es) * 2010-07-16 2012-12-10 Consejo Superior De Investigaciones Científicas (Csic) Proceso de obtención de derivados solubles en agua de 20 (s) camptotecina como agentes antitumorales.
US20140086975A1 (en) 2010-10-15 2014-03-27 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
AU2019247434A1 (en) * 2018-04-06 2020-10-08 Seagen Inc. Camptothecin Peptide Conjugates
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
CN110590796B (zh) * 2018-06-12 2022-07-15 青岛海洋生物医药研究院股份有限公司 喜树碱衍生物及其制备方法和应用
HRP20231619T1 (hr) * 2019-04-26 2024-04-26 Immunogen, Inc. Derivati kamptotecina
KR20240049583A (ko) * 2021-08-19 2024-04-16 심시어 자이밍 파마슈티컬 컴퍼니 리미티드 캄프토테신 유도체, 이의 약학 조성물 및 이의 응용

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012096832A3 (en) * 2011-01-12 2013-01-10 Crystal Biopharmaceutical Llc Hdac inhibiting derivatives of camptothecin
US8980909B2 (en) 2011-01-12 2015-03-17 Crystal Biopharmaceutical Llc HDAC inhibiting derivatives of camptothecin

Also Published As

Publication number Publication date
IS1708B (is) 1998-12-16
JP2000109475A (ja) 2000-04-18
SK323792A3 (en) 1998-09-09
OA09767A (en) 1993-11-30
FI982185L (fi) 1998-10-08
NO924158L (no) 1993-04-30
JPH05222048A (ja) 1993-08-31
HU9203384D0 (en) 1993-01-28
JP3020760B2 (ja) 2000-03-15
HU211349A9 (en) 1995-11-28
FI982185A0 (fi) 1998-10-08
NO302073B1 (no) 1998-01-19
JP3229298B2 (ja) 2001-11-19
AU657007B2 (en) 1995-02-23
CN1072683A (zh) 1993-06-02
RU2119921C1 (ru) 1998-10-10
CA2081580A1 (en) 1993-04-30
FI924878A7 (fi) 1993-04-30
NZ244914A (en) 1995-01-27
EP0540099B1 (en) 1996-04-17
GR3020120T3 (en) 1996-08-31
IL103571A (en) 1998-01-04
FI982185A7 (fi) 1998-10-08
ES2086643T3 (es) 1996-07-01
SK279298B6 (sk) 1998-09-09
ATE136898T1 (de) 1996-05-15
DE69209969T2 (de) 1996-09-12
DE69209969D1 (de) 1996-05-23
TW221994B (OSRAM) 1994-04-01
MX9206211A (es) 1993-05-01
HUT65719A (en) 1994-07-28
DK0540099T3 (da) 1996-06-17
NO924158D0 (no) 1992-10-28
FI104373B (fi) 2000-01-14
FI20021090A7 (fi) 2002-06-07
HU217970B (hu) 2000-05-28
FI20021090L (fi) 2002-06-07
IS3936A (is) 1993-04-30
CZ323792A3 (en) 1993-10-13
AU2738592A (en) 1993-05-06
EP0540099A1 (en) 1993-05-05
IL103571A0 (en) 1993-03-15
AP306A (en) 1994-01-28
AP9200439A0 (en) 1992-10-31
FI924878A0 (fi) 1992-10-28
CZ284023B6 (cs) 1998-07-15
MY108261A (en) 1996-09-30

Similar Documents

Publication Publication Date Title
KR100246154B1 (ko) 수용성 캠프토테신 유도체
US5559235A (en) Water soluble camptothecin derivatives
US5342947A (en) Preparation of water soluble camptothecin derivatives
US6100273A (en) Water soluble camptothecin derivatives
KR0178808B1 (ko) 인체 결장직장암의 효능있는 억제제로서의 캠프토테신 동족체
US5126351A (en) Antitumor compounds
US5401747A (en) Alkyl camptothecin compounds as potent inhibitors of human colorectal cancer
AU781300B2 (en) New dihydrofuro (3,4-b) quinolin-1-one compounds, a process for their preparation and pharmaceutical compositions containing them
AU638205B2 (en) Optically pure r-(-)-niguldipine and its derivatives for treating tumorous diseases
EP0696285A1 (en) Water soluble derivatives of camptothecin and their use as antitumor agents
EP0711767B1 (en) Antineoplastic cyclolignan derivatives
SI9300183A (sl) Vodotopni kamptotecinski derivati
PL173684B1 (pl) Pochodne kamptotecyny i sposób wytwarzania pochodnych kamptofecyny
KR800001287B1 (ko) 치환된 아릴알킬 아민의 제조방법

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20081014

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20091204

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20091204